Status: Recruiting
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Participants needed: 50
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Aurigene Discovery Technologies LimitedUpdated: Apr 17, 2026Locations: 37
Eligibility criteria
Males and females ≥ 18 years of age. [+12]
Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immun... [+17]